vs
Medpace Holdings, Inc.（MEDP）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Medpace Holdings, Inc.的1.1倍（$772.1M vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs 12.7%，领先6.3%），Medpace Holdings, Inc.同比增速更快（32.0% vs 5.9%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $161.8M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 9.0%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MEDP vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$708.5M
营收增速更快
MEDP
高出26.2%
5.9%
净利率更高
MEDP
高出6.3%
12.7%
自由现金流更多
MEDP
多$26.3M
$161.8M
两年增速更快
MEDP
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $772.1M |
| 净利润 | $135.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | 14.5% |
| 净利率 | 19.1% | 12.7% |
| 营收同比 | 32.0% | 5.9% |
| 净利润同比 | 15.5% | 3.9% |
| 每股收益（稀释后） | $4.65 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRVTY
| Q4 25 | $708.5M | $772.1M | ||
| Q3 25 | $659.9M | $698.9M | ||
| Q2 25 | $603.3M | $720.3M | ||
| Q1 25 | $558.6M | $664.8M | ||
| Q4 24 | $536.6M | $729.4M | ||
| Q3 24 | $533.3M | $684.0M | ||
| Q2 24 | $528.1M | $691.7M | ||
| Q1 24 | $511.0M | $649.9M |
净利润MEDPRVTY
| Q4 25 | $135.1M | $98.4M | ||
| Q3 25 | $111.1M | $46.7M | ||
| Q2 25 | $90.3M | $53.9M | ||
| Q1 25 | $114.6M | $42.2M | ||
| Q4 24 | $117.0M | $94.6M | ||
| Q3 24 | $96.4M | $94.4M | ||
| Q2 24 | $88.4M | $55.4M | ||
| Q1 24 | $102.6M | $26.0M |
毛利率MEDPRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率MEDPRVTY
| Q4 25 | 21.6% | 14.5% | ||
| Q3 25 | 21.5% | 11.7% | ||
| Q2 25 | 20.9% | 12.6% | ||
| Q1 25 | 20.3% | 10.9% | ||
| Q4 24 | 23.4% | 16.3% | ||
| Q3 24 | 21.1% | 14.3% | ||
| Q2 24 | 19.9% | 12.4% | ||
| Q1 24 | 20.4% | 6.8% |
净利率MEDPRVTY
| Q4 25 | 19.1% | 12.7% | ||
| Q3 25 | 16.8% | 6.7% | ||
| Q2 25 | 15.0% | 7.5% | ||
| Q1 25 | 20.5% | 6.4% | ||
| Q4 24 | 21.8% | 13.0% | ||
| Q3 24 | 18.1% | 13.8% | ||
| Q2 24 | 16.7% | 8.0% | ||
| Q1 24 | 20.1% | 4.0% |
每股收益（稀释后）MEDPRVTY
| Q4 25 | $4.65 | $0.86 | ||
| Q3 25 | $3.86 | $0.40 | ||
| Q2 25 | $3.10 | $0.46 | ||
| Q1 25 | $3.67 | $0.35 | ||
| Q4 24 | $3.67 | $0.77 | ||
| Q3 24 | $3.01 | $0.77 | ||
| Q2 24 | $2.75 | $0.45 | ||
| Q1 24 | $3.20 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $7.3B |
| 总资产 | $2.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPRVTY
| Q4 25 | $497.0M | $919.9M | ||
| Q3 25 | $285.4M | $931.4M | ||
| Q2 25 | $46.3M | $991.8M | ||
| Q1 25 | $441.4M | $1.1B | ||
| Q4 24 | $669.4M | $1.2B | ||
| Q3 24 | $656.9M | $1.2B | ||
| Q2 24 | $510.9M | $2.0B | ||
| Q1 24 | $407.0M | $1.7B |
股东权益MEDPRVTY
| Q4 25 | $459.1M | $7.3B | ||
| Q3 25 | $293.6M | $7.4B | ||
| Q2 25 | $172.4M | $7.6B | ||
| Q1 25 | $593.6M | $7.6B | ||
| Q4 24 | $825.5M | $7.7B | ||
| Q3 24 | $881.4M | $7.9B | ||
| Q2 24 | $763.6M | $7.9B | ||
| Q1 24 | $671.5M | $7.8B |
总资产MEDPRVTY
| Q4 25 | $2.0B | $12.2B | ||
| Q3 25 | $1.8B | $12.1B | ||
| Q2 25 | $1.6B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B | ||
| Q1 24 | $1.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 26.6% | 21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.43× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $681.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MEDPRVTY
| Q4 25 | $192.7M | $182.0M | ||
| Q3 25 | $246.2M | $138.5M | ||
| Q2 25 | $148.5M | $134.3M | ||
| Q1 25 | $125.8M | $128.2M | ||
| Q4 24 | $190.7M | $174.2M | ||
| Q3 24 | $149.1M | $147.9M | ||
| Q2 24 | $116.4M | $158.6M | ||
| Q1 24 | $152.7M | $147.6M |
自由现金流MEDPRVTY
| Q4 25 | $188.1M | $161.8M | ||
| Q3 25 | $235.5M | $120.0M | ||
| Q2 25 | $142.4M | $115.5M | ||
| Q1 25 | $115.8M | $112.2M | ||
| Q4 24 | $183.0M | $149.8M | ||
| Q3 24 | $138.5M | $125.6M | ||
| Q2 24 | $103.5M | $136.6M | ||
| Q1 24 | $147.2M | $129.7M |
自由现金流率MEDPRVTY
| Q4 25 | 26.6% | 21.0% | ||
| Q3 25 | 35.7% | 17.2% | ||
| Q2 25 | 23.6% | 16.0% | ||
| Q1 25 | 20.7% | 16.9% | ||
| Q4 24 | 34.1% | 20.5% | ||
| Q3 24 | 26.0% | 18.4% | ||
| Q2 24 | 19.6% | 19.7% | ||
| Q1 24 | 28.8% | 20.0% |
资本支出强度MEDPRVTY
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 2.0% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 1.1% | 2.7% |
现金转化率MEDPRVTY
| Q4 25 | 1.43× | 1.85× | ||
| Q3 25 | 2.22× | 2.97× | ||
| Q2 25 | 1.65× | 2.49× | ||
| Q1 25 | 1.10× | 3.03× | ||
| Q4 24 | 1.63× | 1.84× | ||
| Q3 24 | 1.55× | 1.57× | ||
| Q2 24 | 1.32× | 2.87× | ||
| Q1 24 | 1.49× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
